Clinical Trials · NCT02827708
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 324
- Start date
- Sep 2016
- Locations
- 117 sites, 8 countries
- Primary endpoint
- Change in HbA1c